BIO 是一个面向去中心化科学(DeSci)的策展和流动性协议。我们的使命是通过赋予全球患者、科学家和生物技术专业人士共同资助、构建和拥有生物技术项目和知识产权(IP)的能力,从而加速生物技术的发展。
BIO 背后的团队帮助创建了 Molecule,这是一个面向早期生物医学的代币化平台,以及 VitaDAO,这是最大的去中心化长寿科学社区。在这些成功的基础上,BIO 被设计用来通过去中心化的资金、激励和流动性来推动链上的科学经济。
BIO 代币让持有者能够访问 BIO 的科学社区网络和知识产权,从而广泛参与 DeSci 经济。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BIO. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BIO is a Sell candidate.
BIO stock price ended at $0.045388 on 星期日, after dropping 0.69%
On Jan 18, 2026 00:00, the price of BIO fell by 0.69%, dropping from $0.047014 to $0.045388 with 24h trading volume reaching $17.2M BIO.